Saccharomyces boulardii DBVPG 6763

Overview

Saccharomyces boulardii DBVPG 6763 is a specific strain of the probiotic yeast Saccharomyces cerevisiae variant boulardii, recognized for its gastrointestinal supportive effects. Unlike bacterial probiotics, it is a non-pathogenic, transient yeast that survives stomach acid, bile salts, and antibiotics, making it ideal during antimicrobial therapy.¹² Primarily used to support bowel transit, reduce diarrhea, and maintain microbial balance, it competes with pathogens for space and nutrients while promoting mucosal health.³⁴ Discovered in the 1920s from lychee and mangosteen peels in Southeast Asia, S. boulardii has been studied extensively since the 1960s for treating antibiotic-associated diarrhea and infections like Clostridium difficile. This strain, DBVPG 6763, has been tested in clinical trials for reducing inflammation and improving body composition in obese individuals.³

Forms and Variations

Saccharomyces boulardii DBVPG 6763 is typically available in gastro-resistant capsules to protect against stomach acid, ensuring delivery to the intestines. Common formulations provide 5.0 × 10⁹ CFU per capsule, often combined with antioxidants like superoxide dismutase (SOD) for enhanced anti-inflammatory effects.³ Other variations include freeze-dried powders, vegetarian capsules (up to 9 billion CFU), and lactose-free options, which are stomach acid-resistant and temperature-stable.⁵⁶ Strain-specific products verify DBVPG 6763 via genetic typing for efficacy. Choose gastro-resistant forms for better survival through gastric transit; combinations with SOD may benefit metabolic health, while standalone high-CFU capsules suit general gut support. Avoid non-verified strains, as genetic differences affect function, like impaired galactose use enhancing growth at body temperature.¹

Dosage and Administration

Recommended dosages for S. boulardii DBVPG 6763 include 5.0 × 10⁹ CFU twice daily (total 10 billion CFU/day), taken with meals for 60 days in clinical studies on obesity and inflammation.³ General adult use ranges from 250-500 mg (5-10 billion CFU) 1-2 times daily for diarrhea prevention or treatment.⁷ Take capsules whole with water, ideally during or after meals to minimize acid exposure. It can be used alongside antibiotics due to resistance, continuing 1-2 weeks post-therapy. For children, halve adult doses under medical guidance. Frequency: daily for acute issues (up to 2 weeks), or ongoing for maintenance. Best practices: store in cool, dry place; no refrigeration needed due to stability.²

Scientific Research and Mechanism of Action

Key studies on DBVPG 6763 show a 60-day regimen (5 × 10⁹ CFU twice daily with SOD) reduced inflammatory markers (CRP, TNF-α, IL-6) and improved body composition in obese adults (BMI 30-35), via antioxidant and anti-inflammatory actions.³ S. boulardii adheres to pathogens, neutralizes toxins (e.g., from C. difficile), and cleaves virulence factors. It inhibits NF-κB and MAP kinases, reducing IL-8 and pro-inflammatory cytokines while restoring glutathione and epithelial barrier function.¹ Mechanisms include boosting secretory IgA, short-chain fatty acids for colon nourishment, and enzyme stimulation for nutrient absorption. It reduces chloride secretion to treat diarrhea and modulates immunity without promoting antibiotic resistance.¹² Research is promising for IBS, ulcerative colitis, and infections, but larger trials are needed for DBVPG 6763 specifically. Current evidence supports its safety and efficacy in diverse GI conditions.⁴

Benefits and Potential Uses

Proven benefits include preventing and treating antibiotic-associated diarrhea, C. difficile infections, and traveler"s diarrhea by depriving pathogens of adhesion sites and nutrients.¹⁴ It supports healthy bowel transit, reduces inflammation in IBS (abdominal pain, bloating), and aids ulcerative colitis/Crohn"s by promoting mucosal healing and immune balance.⁴ In obesity trials, DBVPG 6763 lowered inflammation and adiposity markers.³ Additional uses: enhances microbial balance, increases IgA and short-chain fatty acids, improves tight junctions for better nutrient absorption, and blocks toxins.²⁵ Potential for immune support via anti-inflammatory cytokines and protection against Salmonella/E. coli. Effective across ages for acute diarrhea, chronic gut issues, and during antibiotics.⁷

Side Effects and Risks

Generally well-tolerated, common side effects are rare and mild, including gas, bloating, or constipation in sensitive individuals.⁷ As a yeast, rare fungemia risks occur in immunocompromised patients (e.g., central lines, ICU). Not for those with yeast allergies. Contraindications: severe immunosuppression, short bowel syndrome. Healthy individuals face minimal risks due to its transient, non-colonizing nature.¹⁶ Monitor for allergic reactions. Pregnant/lactating women should consult doctors, though studies show safety.⁷

Interactions and Precautions

No significant drug interactions; its antibiotic resistance allows co-administration.¹ May enhance antifungals" effects indirectly. Precautions for immunocompromised (avoid high doses), ICU patients, or those with catheters due to rare fungemia.⁷ Safe pre/post-surgery for gut support, but consult for procedures involving immunosuppression. Not for galactose-intolerant (strain-specific trait). Specific populations: children (lower dose), elderly (monitor), pregnant (limited data, physician approval). Discontinue if infection suspected.²

Impact on Biomarkers

DBVPG 6763 reduces inflammatory biomarkers like CRP, TNF-α, IL-1β, IL-6; improves pro/antioxidant ratio with SOD.³ Lowers HOMA-IR, glucose, insulin in metabolic studies. Boosts secretory IgA, short-chain fatty acids; may normalize lipid profiles. Enhances glutathione, reduces intestinal permeability markers.¹

Overdose and Toxicity

No established toxicity; well-tolerated up to 20 billion CFU/day short-term. Excess may cause mild GI upset. No upper limit defined, but exceed 10 billion CFU/day only under supervision. Fungemia rare in vulnerable groups; symptoms include fever, chills—seek immediate care. Transient nature limits accumulation.⁷⁶

Disclaimer

The information provided in this document is for educational purposes only and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.